2008 NSTI Nanotechnology Conference and Trade Show - Nanotech 2008 - 11th Annual

Partnering Events:

TechConnect Summit
Clean Technology 2008

Intranasal Delivery of Insulin via Microemulsion-based Formulation

S. Botner, H.V. Levy, A.C. Sintov
Ben Gurion University of the Negev, IL

Insulin, diabetes, microemulsion, intranasal delivery

Nasal drug administration has been proposed as an alternative to parenteral injection. Because of their unique solubilization and permeation enhancing properties, microemulsions possess a great potential as an intranasal drug delivery system for insulin. The most common regimen of insulin treatment is the subcutaneous injection of fast acting insulin preprandial. We developed a novel microemulsion which eliminates the use of integrated alcohol or other irritant chemicals and contains GRAS compounds. Two microemulsion types were prepared, ME-50 and ME-20, containing 50 and 20% aqueous phase, respectively. Four different administrations were tasted on six diabetic New Zealand White rabbits: subcutaneous injection of 0.5 I.U/kg Humalog solution, intravenous injection of 0.5 I.U/kg Humalog solution, intranasal administration of 1 IU/kg microemulsion type MEIN-50 (40µL/one nostril), and intranasal administration of 1 IU/kg microemulsion type MEIN-20 (50µL/nostril X 2 nostrils). Blood samples were collected for further ELISA analysis. Intranasal application resulted in a faster tmax than subcutaneous injection (15.00±0 vs. 27.5±11.29 min), the relative bioavailability (as compared with subcutaneous administration) and the absolute bioavailability (as compared with intravenous administration) found to be 21.53% and 41.82%, respectively. The present results clearly show that the new microemulsion possesses a great potential for the treatment of diabetes patients.

Nanotech 2008 Conference Program Abstract